Financial Assets Valuation Report: Agilent, Alexion, Allergan

This report provides a financial assets valuation for three companies: Agilent Technologies Inc, Alexion Pharmaceuticals Inc, and Allergan plc. The introduction provides an overview of Agilent Technologies, its products including systematic and measurement instruments, and its revenue. The report discusses Agilent's major subdivisions between Products and Services in food and nourishment, forensic and environmental, pharmaceutical, diagnostics, and chemical and energy. Alexion Pharmaceuticals Inc, a biopharmaceutical company focused on rare diseases, is then examined, including its key product, Soliris, and its global presence. Finally, the report analyzes Allergan plc, a pharmaceutical company specializing in generic drugs and branded pharmaceuticals, highlighting its major brands and contributions to research and development. The report concludes by referencing the sources used.

Financial Assets Valuation

Financial Assets Valuation 2
Agilent Technologies Inc
Introduction
The chemical market, diagnostics, and life science are ruling by Agilent Technologies Inc and
have a quantifiable effect on the scientific world. Agilent Technologies was founded in Santa
Clara, California and currently 12,500 employees working in it. Agilent Technologies is a
leading maker of scientific testing equipment and provides laboratories all-inclusive with
instruments, services, consumables, applications and expertise and provide customers the proper
guidance for their problems and empowering clients to pick up the product and services they are
looking for. Agilent earns U.S. $4.20 billion revenue in 2016 (Agilent | Company
Information.2017).
Products Agilent Technology supply
Agilent supplies a large number of systematic and measurement instruments, including, mass
spectrometers, gas and fluid chromatographs, anatomic pathology workflows, vacuum pumps,
genetic and diagnostic instruments and devices. Its operations incorporate items utilized as a part
of nourishment, compound investigation, energy and life sciences, crime scene investigation
instruments and an environment.
Major subdivision between Products and Services Company provides:
Food and nourishment: Agilent provides technologies to test the global food supply and just
make sure that the food people are consuming is free of containments like bacterial, viral,
chemical or microbiological.

Financial Assets Valuation 3
Forensic and environmental: Agilent offers the fastest, sensitive and safe methods for
observing contaminants which can affect the quality of life, products from pesticides to
pharmaceutical residues to trace metals are major product Agilent deals with.
Pharmaceutical: Agilent has one of the broadest solutions arrangements of any organization
serving the pharmaceutical business.
Diagnostics: provides possible diagnostics for the fight against diseases like cancer and claim
that there path laboratories serve fast and accurate information.
Chemical and Energy: Agilent claim their solution are helpful for customers those who want to
predict the failure and production in their refineries
Research: Agilent claims that their software, instruments and sample preparation solutions help
scientists conduct faster, more accurate research.
Agilent Technologies Inc successfully gets the highest sales outside the US and created his new
company in late 2014 which deals in electronic measurements. There are numerous expertise and
trusted collaboration which helps Agilent to become the leader of life science and chemical
market.
Alexion Pharmaceuticals Inc
Alexion is focused on developing and delivering life-transforming therapies for patients with
devastating and rare diseases. Alexion Pharmaceuticals Inc is situated in New Haven,

Financial Assets Valuation 4
Connecticut, United States and was founded in 1992 by Leonard bell. David R.
Brennan becomes the current CEO of Alexion on December 12, 2016. Alexion is a global
biopharmaceutical company cure patients with life-threatening diseases which have no effective
treatment in medical science. People trust and depend on give them the motivation to driven and
deliver medical breakthroughs where none currently exist. Since 2006, Alexion has been a
supporter of healthcare research and quality studies at Duke University for aspirin (Alexion: A
Global Biopharmaceutical Company. 2017).
ADVANCE PRODUCTS SERVED BY ALEXION PHARMACEUTICALS INC
Soliris (eculizumab) developed by Alexion pharmaceuticals Inc the world's first approved
terminal complement inhibitor, from the laboratory through commercialization.
Patients with paroxysmal nocturnal hemoglobinuria (PNH) in nearly 50 countries for the
treatment, treated by Soliris and in more than 40 countries for the treatment of patients with a
typical hemolytic uremic syndrome (aHUS) — two life-threatening, ultra-rare disorders caused
by uncontrolled complement activation. After the establishment in 1992, Alexion became a
public company in 1996 (NASDAQ: ALXN). Alexion's approximately 3,000 employees around
the world serve patients in 50 countries.
Today, Alexion is propelling the most powerful uncommon ailment pipeline in the biotech
business, which, notwithstanding our supplement and metabolic clinical projects, incorporates
more than 30 different preclinical projects over a scope of helpful modalities. Alexion claims
that they continue to expand their business to serve more patients in additional countries.

Financial Assets Valuation 5
Allergan plc
Allergan Plc is focused on producing generic drugs, commercializing and manufacturing branded
multinational pharmaceuticals and performs pharmaceutical research and development. Initially
in 2015 Allergan was known as Actavis, Plc. Allergan was founded in Dublin, Ireland, which
came up as a leader of new industry model-growth Pharma. Allergan focused on producing and
manufacturing biological products for different commercial and developing brands to serve their
services to patients around the world.
Major leading brands and products for the central nervous system, medical aesthetics,
dermatology and eye care have been served by Allergan markets. Allergan markets deal with
women's health, gastroenterology, urology and anti-infective therapeutic categories.
Allergan contribution in R & D and Open Science
Allergan works for the betterment of patients and contributes game-changing ideas and
innovation in open science. Allergan served in the development of pipelines in the
pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development. Allergan
contributes in the employment of 16000 global colleagues those are committed to being bold for
Life. Currently, Allergan has commercial operations in approximately 100 countries. With the
commitment of providing healthier life to people around the world, Allergan commits working
with physicians, healthcare providers and patients to deliver innovative and meaningful
treatments.

Financial Assets Valuation 6
REFERENCES
Agilent | Company Information.(2017) Agilent.co.in.
http://www.agilent.co.in/about/companyinfo/
Alexion: A Global Biopharmaceutical Company. (2017). http://www.alexion.com/about-alexion-
pharmaceuticals
About (2017). Allergan.com, from https://www.allergan.com/home
Cooper, C. A., & Bergamini, M. V. (1980). U.S. Patent No. 4,230,724. Washington, DC: U.S.
Patent and Trademark Office.